iStock_000014402664MediumFDANews.com released a statement that “Abbott Laboratories announced its purchase of Tendyne Holdings Inc., a medical device company focused on developing minimally invasive mitral valve replacement therapies, for $250 million plus potential future payments tied to regulatory milestones.”  For more information on this acquisition, please visit: http://www.fdanews.com/articles/172387-abbott-buys-tendyne-for-250-million